These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 16209113)

  • 21. Therapeutic dendritic cell vaccination of patients with renal cell carcinoma.
    Berntsen A; Geertsen PF; Svane IM
    Eur Urol; 2006 Jul; 50(1):34-43. PubMed ID: 16675096
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor escape from the immune response: a major hurdle for successful immunotherapy of cancer?
    Chouaib S
    Tunis Med; 2005 Dec; 83 Suppl 12():7-10. PubMed ID: 16430055
    [No Abstract]   [Full Text] [Related]  

  • 23. Optimal control in a model of dendritic cell transfection cancer immunotherapy.
    Castiglione F; Piccoli B
    Bull Math Biol; 2006 Feb; 68(2):255-74. PubMed ID: 16794930
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant immunotherapy in colorectal cancer.
    Vermorken JB
    Semin Oncol; 2000 Oct; 27(5 Suppl 10):66-71. PubMed ID: 11049049
    [No Abstract]   [Full Text] [Related]  

  • 25. Harnessing the immune system for ovarian cancer therapy.
    Odunsi K; Sabbatini P
    Am J Reprod Immunol; 2008 Jan; 59(1):62-74. PubMed ID: 18154597
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical results of vaccine therapy for cancer: learning from history for improving the future.
    Choudhury A; Mosolits S; Kokhaei P; Hansson L; Palma M; Mellstedt H
    Adv Cancer Res; 2006; 95():147-202. PubMed ID: 16860658
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Suppressive influences in the immune response to cancer.
    Bronte V; Mocellin S
    J Immunother; 2009 Jan; 32(1):1-11. PubMed ID: 19307988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hsp-based tumor vaccines: state-of-the-art and future directions.
    Takakura Y; Takemoto S; Nishikawa M
    Curr Opin Mol Ther; 2007 Aug; 9(4):385-91. PubMed ID: 17694451
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaccine therapy for renal cancer.
    Amato RJ
    Expert Rev Vaccines; 2008 Sep; 7(7):925-35. PubMed ID: 18767943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A neoadjuvant/adjuvant randomized trial of colorectal cancer patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55.
    Ullenhag GJ; Spendlove I; Watson NF; Indar AA; Dube M; Robins RA; Maxwell-Armstrong C; Scholefield JH; Durrant LG
    Clin Cancer Res; 2006 Dec; 12(24):7389-96. PubMed ID: 17121873
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantification and phenotypic characterization of circulating tumor cells for monitoring response to a preventive HER2/neu vaccine-based immunotherapy for breast cancer: a pilot study.
    Stojadinovic A; Mittendorf EA; Holmes JP; Amin A; Hueman MT; Ponniah S; Peoples GE
    Ann Surg Oncol; 2007 Dec; 14(12):3359-68. PubMed ID: 17906897
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccine therapy in patients with renal cell carcinoma.
    Van Poppel H; Joniau S; Van Gool SW
    Eur Urol; 2009 Jun; 55(6):1333-42. PubMed ID: 19201522
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.
    Xia D; Moyana T; Xiang J
    Cell Res; 2006 Mar; 16(3):241-59. PubMed ID: 16541123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Peptide vaccination therapy for malignant glioma].
    Yamanaka R; Itoh K
    Brain Nerve; 2007 Mar; 59(3):251-61. PubMed ID: 17370651
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols.
    Lundberg K; Roos AK; Pavlenko M; Leder C; Wehrum D; Guevara-Patiño J; Andersen RS; Pisa P
    Vaccine; 2009 Mar; 27(10):1557-65. PubMed ID: 19171173
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasmid DNA- and messenger RNA-based anti-cancer vaccination.
    Weide B; Garbe C; Rammensee HG; Pascolo S
    Immunol Lett; 2008 Jan; 115(1):33-42. PubMed ID: 18006079
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines.
    Yamaguchi S; Tatsumi T; Takehara T; Sakamori R; Uemura A; Mizushima T; Ohkawa K; Storkus WJ; Hayashi N
    Cancer; 2007 Oct; 110(7):1469-77. PubMed ID: 17685394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent advances in heat shock protein-based cancer vaccines.
    Wang HH; Mao CY; Teng LS; Cao J
    Hepatobiliary Pancreat Dis Int; 2006 Feb; 5(1):22-7. PubMed ID: 16481277
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Developing enabling technologies for the success of cancer immunotherapy.
    Sznol M
    Curr Opin Investig Drugs; 2004 Dec; 5(12):1239-42. PubMed ID: 15648943
    [No Abstract]   [Full Text] [Related]  

  • 40. Advances in specific immunotherapy for prostate cancer.
    Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
    Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.